Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Learn more about:
Related Clinical Trial
Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma FLUOPANC-trial – Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma QoL After Liver Surgery CH-EUS in Diagnosis of Inoperable Bile Duct Tumors Treatment of ARB202 Advanced Gastrointestinal Cancer Patients Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Molecular Epidemiology of Biliary Tree Cancers Prognostic Factors in Periampullary Tumors and Cysts RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor Deep Liver Phenotyping and Immunology Study A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry. Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone Crossover Relative Bioavailability and Dose Escalation Study of TT-00420 Tablet in Patients With Advanced Solid Tumors Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Official Title

Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma

Brief Summary

      Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy
      in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the
      homologous recombination deficient (HRD) signature.

Study Phase

Phase 2

Study Type


Primary Outcome

Progression Free Survival (PFS)

Secondary Outcome

 Objective Response Rate (ORR)





Study Arms / Comparison Groups

 Investigational Group
Description:  Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1
Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 11, 2021

Completion Date

September 2023

Primary Completion Date

September 2022

Eligibility Criteria

        Inclusion Criteria:

        Subject must meet all of the following applicable inclusion criteria to participate in this

          -  Written informed consent and HIPAA authorization for release of personal health
             information prior to registration. NOTE: HIPAA authorization may be included in the
             informed consent or obtained separately.

          -  Age ≥ 18 years at the time of consent.

          -  ECOG Performance Status of 0-1 within 14 days prior to registration.

          -  Histological or cytological documentation of metastatic adenocarcinoma of the biliary
             tract per AJCC, 8th edition.

          -  Measurable disease according to RECIST 1.1 within 28 days prior to registration.

          -  Must have a defined HRD signature (BRCA1, BRCA2, PALB2, MRE, CHEK1, CHEK2, PTEN, ATM,
             ATR, BER, RPA1, RAD51, BARD1, BRIP1, FAAP20, FANCM, FAN1, NBN, EMSY, MRE11, ARID1A,
             BAP-1.) NOTE: Clinical Laboratory Improvement Act (CLIA)-certified assays including
             commercial tests (Foundation Medicine, Caris, Tempus, Guardant 360 or other platforms
             of next generation sequencing) will be allowed.

          -  Patients must have achieved complete response (CR), partial response (PR) or stable
             disease (SD) after 4 to 6 months of any platinum-based therapy.

          -  Prior treatment with immune therapy is allowed. Exception: prior treatment with PARP
             inhibitors is not allowed.

          -  Prior cancer treatment must be completed at least 21 days prior to registration.
             Toxicities attributed to prior therapy/procedure must have resolved to Grade ≤ 1.
             Exceptions include alopecia and oxaliplatin induced neurotoxicity ≤ Grade 2. C1D1
             treatment will start no more than 28 days after completion of prior cancer treatment.
             Patients that are > 28 days from completion of prior treatment will need to be
             discussed with the sponsor-investigator.

          -  Life expectancy of ≥ 16 weeks per estimation of site investigator.

          -  Demonstrate adequate organ function as defined in the table in the protocol. All
             screening labs to be obtained within 7 days prior to registration.

          -  Negative urine or serum pregnancy test done ≤ 72 hours prior to C1D1 for women of
             childbearing potential.

          -  Women of childbearing potential and their partners, who are sexually active, must
             agree to the use contraception as described in the protocol.

          -  Male patients must use contraception as described in the protocol.

          -  Participants with known Hepatitis B viral infection that is controlled on
             nucleos(t)ide analogs (eg entecavir or tenofovir) per investigator discretion and will
             be continued for the duration of the study are eligible. NOTE: Risk of HBV
             reactivation should be considered in all patients and the need for anti-HBV
             prophylaxis should be carefully assessed prior to the initiation of anticancer
             therapy. Testing is not required at screening. Status should be assessed through
             medical history and if there is a question testing may be done at the discretion of
             the investigator based on local guidelines. This testing would be considered standard
             of care.

          -  Participants who are Hepatitis C antibody positive but Hepatitis C RNA negative due to
             prior treatment or natural resolution of infection are eligible. Testing is not
             required at screening. Status should be assessed through medical history and if there
             is a question testing may be done at the discretion of the investigator based on local
             guidelines. This testing would be considered standard of care.

          -  Participants known to be human immunodeficiency virus (HIV) serologically positive are
             eligible if they meet ALL of the following criteria:

               -  Cluster of differentiation 4 ≥ 350/µL and viral load < 400 copies/mL

               -  No history of acquired immunodeficiency syndrome-defining opportunistic
                  infections within 12 months prior to registration

               -  No history of HIV associated malignancy for the past 5 years

               -  Concurrent antiretroviral therapy as per the most current National Institutes of
                  Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and
                  Adolescents Living with HIV started > 4 weeks prior to study registration NOTE:
                  Testing is not required at screening. Status should be assessed through medical
                  history and if there is a question testing may be done at the discretion of the
                  investigator based on local guidelines. This testing would be considered standard
                  of care.

          -  Patients must agree to not donate blood during the study or for 90 days after the last
             dose of study treatment.

        Exclusion Criteria

        Subjects meeting any of the criteria below may not participate in the study:

          -  Patient is simultaneously enrolled in any interventional clinical trial.

          -  Tumor embolization ≤ 4 weeks prior to registration.

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism ≤ 6
             months prior to registration.

          -  Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE
             v5.0 grade 3, ≤ 4 weeks prior to registration.

          -  Radiotherapy encompassing > 20% of the bone marrow within 2 weeks prior to
             registration. Palliative radiation therapy to a small field >1 week prior to Day 1 of
             study treatment may be allowed.

          -  Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days prior
             to registration AND have recovered from surgery.

          -  Congestive heart failure - New York Heart Association (NYHA) ≥ Class II.

          -  Uncontrolled cardiac conditions (eg. unstable ischemia, uncontrolled symptomatic
             arrhythmia, cardiac arrhythmias requiring anti-arrhythmic therapy, corrected QT
             interval by Fridericia's correction formula (QTcF) prolongation > 500 ms, or patients
             with congenital long QT syndrome. NOTE: Pacemaker, beta blockers or digoxin are

          -  Ongoing infection > Grade 2 National Cancer Institute (NCI)-Common Terminology
             Criteria for Adverse Events (CTCAE) version (v)5.0.

          -  Patient taking medications with a known risk to prolong the QTc interval and/or cause
             Torsades de Pointes. NOTE: Patients must be discontinued ≥ 7 days of registration.
             Treating physicians may wish to replace the drug(s) that do not carry this risk with
             safe alternative(s).

          -  Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure >
             90 mmHg despite optimal medical management).

          -  Seizure disorder requiring medication.

          -  Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain
             metastases, or radiologic signs of CNS hemorrhage. NOTE: Participants with
             asymptomatic brain metastases (i.e. off corticosteroids and anticonvulsants for at
             least 7 days) are permitted.

          -  Non-healing wound, ulcer, or bone fracture.

          -  Renal failure requiring hemo-or peritoneal dialysis.

          -  Steroid use of > than the equivalence of 5 mg of prednisone.

          -  Participant must not have a history of interstitial lung disease.

          -  Any autoimmune disease that has required systemic treatment in the past 2 years (ie,
             with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement
             therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of
             systemic treatment.

          -  Participant has a diagnosis of immunodeficiency or has received systemic steroid
             therapy or any other form of immunosuppressive therapy within 7 days prior to
             initiating protocol therapy.

          -  Participant has received a transfusion (platelets or red blood cells) ≤ 4 weeks prior
             to initiating protocol therapy.

          -  Participant has received colony stimulating factors (e.g., granulocyte
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.

          -  Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due
             to prior chemotherapy that persisted > 4 weeks and was related to the most recent

          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation.

          -  Unable to swallow orally administered medications.

          -  Any malabsorption condition and/or patients with gastrointestinal disorders likely to
             interfere with absorption of the study medication.

          -  History of organ allograft including stem cell or cord blood transplantation.

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens. Patients considered a poor medical risk due to a serious,
             uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled
             infection. Examples include, but are not limited to, uncontrolled ventricular
             arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure
             disorder, unstable spinal cord compression, superior vena cava syndrome, extensive
             interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan
             or any psychiatric disorder that prohibits obtaining informed consent.

          -  Currently receiving any other investigational agent which would be considered as a
             treatment for the primary neoplasm.

          -  Participant must not have had diagnosis, detection, or treatment of another type of
             cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell
             carcinoma of the skin and cervical cancer that has been definitively treated).

          -  Myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of
             myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).

          -  Concurrent use of warfarin or other warfarin-derived anticoagulant. NOTE: Concurrent
             use of heparin, direct oral anticoagulants, low molecular weight heparin (LMWH), or
             fondaparinux is allowed.

          -  Participant taking medications or herbal products including grapefruits, grapefruit
             hybrids, pomelos, star fruits, Seville oranges, pomegranates, or the juice from any of
             these. NOTE: Patients must discontinue the drug/product ≥ 7 days prior to

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          -  Judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results.




18 Years - N/A

Accepts Healthy Volunteers



Walid Shaib, MD, , 

Administrative Informations



Organization ID

HCRN GI19-414

Responsible Party


Study Sponsor

Walid Shaib, MD


 Emory University

Study Sponsor

Walid Shaib, MD, Principal Investigator, Emory University

Verification Date

June 2022